Nachrichten zur Hims & Hers Health Inc. Aktie

Charlotte (www.aktiencheck.de) - Hims & Hers Health-Aktienanalyse von BofA Securities:Allen Lutz, Analyst von BofA Securities, stuft die Aktie von Hims…

Hims & Hers Health, the Healthcare sector company, was revisited by a Wall Street analyst yesterday. Analyst Maria Ripps from…

Canaccord reiterates Hims and Hers stock rating on Novo launch…

Hims & Hers is moving toward branded GLP-1s and deeper pharma partnerships, shifting to a potential platform for drug distribution.…

The average one-year price target for Hims & Hers Health (NYSE:HIMS) has been revised to $25.63 / share. This is…

Low-cost healthcare services provider Hims Hers ($HIMS) on Thursday disclosed the availability of approved versions of Novo Nordisk’s ($NVO)…

Hims and Hers stock price target maintained at $23 by BofA Securities…

Hims and Hers stock price target maintained at $23 by BofA Securities…

Hims and Hers stock price target maintained at $23 by BofA Securities…

US telehealth giant Hims & Hers’ USD 1.15bn acquisition in February of Australian digital health company Eucalyptus is expected to significantly shake…

Key Takeaways: Hims & Hers Health (HIMS) expands its product offerings by selling Novo Nordisks GLP-1 drugs,…

Hims & Hers Health trades at $20.11 today, down 3.50%. Sellers dominate as price stays below key moving averages and…

Hims & Hers now sells Novo Nordisk’s Wegovy and Ozempic for weight loss and type 2 diabetes. Read more here.…

Hims & Hers Health Inc. (HIMS) on Thursday announced the availability of a wide range of Novo Nordisk’s (NVO) GLP-1…